What is the latest ANUHPHR stock price?
The latest stored price for ANUHPHR is Rs 93.48 as of 2026-09-18.
gimli
ANUHPHR stock AI analysis
ANUHPHR Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ANUH PHARMA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available ANUHPHR price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹93.48
1W return
+2.49%
1M return
+23.32%
3M return
+18.48%
6M return
+21.36%
1Y return
+5.96%
Market cap
₹936.89 cr
PE
21.22
PB
2.66
ROE
+13.02%
ROCE
+12.63%
RSI
62.64
Turnover
₹0.90 cr
Why it can matter in screens
- Momentum: ANUHPHR is above 50DMA, above 200DMA; RSI is 62.64.
- Returns: 1D -0.21%, 1W +2.49%, 1M +23.32%, 3M +18.48%, 1Y +5.96%.
- Trend levels: 52W high ₹99.50, 52W low ₹75.00, off high -6.05%.
- Liquidity: latest turnover is ₹0.90 cr; volume vs 20D is +0.32%.
- Valuation/profitability: PE 21.22, PB 2.66, ROE +13.02%, ROCE +12.63%.
- Growth: 3Y sales CAGR +13.52%, 3Y profit CAGR +4.30%.
Quick Answers
Is ANUHPHR above its 50DMA and 200DMA?
ANUHPHR is above 50DMA, above 200DMA. The latest 50DMA is 81.60 and the latest 200DMA is 78.88.
What are ANUHPHR PE, ROE and ROCE?
ANUHPHR has PE 21.22, ROE +13.02%, and ROCE +12.63% in Gimli's latest available snapshot.
How has ANUHPHR performed recently?
ANUHPHR has returned +23.32% over 1 month, +18.48% over 3 months, and +5.96% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 196.89 cr | 19.36 cr | 11.42 cr | 1.14 |
| 2026-03-31 | 202.12 cr | 18.63 cr | 11.68 cr | 1.17 |
| 2025-12-31 | 197.18 cr | 20.91 cr | 13.45 cr | 1.34 |
| 2025-09-30 | 185.88 cr | 12.86 cr | 7.61 cr | 0.76 |
| 2025-06-30 | 186.48 cr | 13.68 cr | 8.30 cr | 0.83 |
| 2025-03-31 | 198.14 cr | 20.07 cr | 12.46 cr | 1.24 |
| 2024-12-31 | 159.51 cr | 15.73 cr | 10.34 cr | 1.03 |
| 2024-09-30 | 165.95 cr | 20.28 cr | n/a | 1.50 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 771.66 cr | 66.08 cr | 41.05 cr | 4.10 |
| 2025-03-31 | 661.51 cr | 70.36 cr | 47.35 cr | 4.72 |
| 2024-03-31 | 647.00 cr | 87.25 cr | 60.06 cr | 5.99 |
| 2023-03-31 | 527.49 cr | 57.39 cr | 36.18 cr | 3.61 |
| 2022-03-31 | 491.84 cr | 52.04 cr | 30.56 cr | 6.10 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 557.37 cr | 8.06 cr | 0.06 cr | 352.22 cr |
| 2025-03-31 | 506.63 cr | 19.56 cr | 10.89 cr | 326.02 cr |
| 2024-03-31 | 445.68 cr | 7.20 cr | 2.69 cr | 291.22 cr |
| 2023-03-31 | 404.98 cr | 1.93 cr | 0.91 cr | 241.22 cr |
| 2022-03-31 | 347.17 cr | 3.80 cr | 4.23 cr | 213.77 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | -3.01 cr | -10.88 cr | n/a |
| 2025-03-31 | 37.12 cr | 16.98 cr | n/a |
| 2024-03-31 | 12.93 cr | 7.91 cr | n/a |
| 2023-03-31 | 53.90 cr | 52.35 cr | n/a |
| 2022-03-31 | 28.86 cr | 27.25 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +71.80% | +0.01% | +0.00% | +0.00% | +28.19% | +0.00% |
| 2026-03-31 | +71.80% | +0.05% | +0.00% | +0.00% | +28.16% | +0.00% |
| 2025-12-31 | +71.82% | +0.00% | +0.00% | +0.00% | +28.18% | +0.00% |
| 2025-09-30 | +71.82% | +0.00% | +0.00% | +0.00% | +28.18% | +0.00% |
| 2025-07-16 | +69.92% | +0.03% | +0.00% | +0.00% | +30.06% | +0.00% |
| 2025-06-30 | +69.92% | +0.04% | +0.00% | +0.00% | +30.04% | +0.00% |
| 2025-03-31 | +69.92% | +0.04% | +0.00% | +0.00% | +30.05% | +0.00% |
| 2024-12-31 | +69.92% | +0.02% | +0.00% | +0.00% | +30.06% | +0.00% |
| 2024-12-17 | +69.92% | +0.02% | +0.00% | +0.00% | +30.06% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze ANUH PHARMA with valuation, momentum and industry peers
- Compare ANUHPHR with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ANUHPHR with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.